Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan
- PMID: 32865575
- PMCID: PMC7489824
- DOI: 10.1001/jamanetworkopen.2020.15189
Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan
Abstract
Importance: It remains unclear whether androgen deprivation therapy (ADT) is associated with subsequent dementia risk in patients with prostate cancer. There are limited data regarding dementia risk across ADT types.
Objective: To examine the association between all-cause dementia, including Alzheimer disease (AD), and different ADT types in patients with prostate cancer.
Design, setting, and participants: This cohort study used linked data from the Taiwan National Cancer Registry, the National Health Insurance Research Database, and the Taiwan National Death Registry. A cohort of 23 651 patients with newly diagnosed prostate cancer between January 1, 2008, and December 31, 2015, was identified and followed up from 1 year after diagnosis until December 31, 2017. Data analysis was performed between January 2019 and May 2020.
Exposures: Patients who received and did not receive ADT, including gonadotropin-releasing hormone (GnRH) agonists, orchiectomy, or antiandrogen monotherapy.
Main outcomes and measures: The primary outcomes were all-cause dementia or AD. Stabilized inverse probability of treatment weighting was used to balance baseline covariates. The association between dementia and various ADT types was examined using the Cox proportional hazards model. Furthermore, a multivariate Cox proportional model with age as the time scale was conducted for complementary comparison.
Results: In the cohort of 23 651 male patients (median [interquartile range] age, 73 [66-79] years), 6904 (29.2%) did not receive ADT, 11 817 (50.0%) received GnRH agonists, 876 (3.7%) received orchiectomy, and 4054 (17.1%) received antiandrogen monotherapy. Overall, 1525 patients were diagnosed with incident dementia (1.72 per 100 person-years) during a median (interquartile range) follow-up of 3.46 (1.92-5.51) years. Compared with those who did not receive ADT, those using antiandrogen monotherapy showed an increased risk of dementia (weighted hazard ratio [HR], 1.34; 95% CI, 1.16-1.55) and AD (weighted HR, 1.52; 95% CI, 1.13-2.04). The risk of dementia was similar between GnRH agonist use or orchiectomy and no ADT use (GnRH agonist: weighted HR, 1.13; 95% CI, 1.00-1.28; orchiectomy: 1.00; 95% CI, 0.74-1.37). Several sensitivity analyses revealed consistent findings for both outcomes.
Conclusions and relevance: In this study, the use of antiandrogen monotherapy was associated with increased risk of dementia or AD, while GnRH agonist use and orchiectomy had no significant difference compared with patients who did not receive ADT. Further prospective studies are warranted to confirm these findings.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7489824/bin/jamanetwopen-e2015189-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7489824/bin/jamanetwopen-e2015189-g002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7489824/bin/jamanetwopen-e2015189-g003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7489824/bin/jamanetwopen-e2015189-g004.gif)
Comment in
-
Urological Oncology: Prostate Cancer.J Urol. 2021 Mar;205(3):930-932. doi: 10.1097/JU.0000000000001564. Epub 2020 Dec 23. J Urol. 2021. PMID: 33356456 No abstract available.
Similar articles
-
Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.Cancer Epidemiol. 2020 Feb;64:101657. doi: 10.1016/j.canep.2019.101657. Epub 2020 Jan 7. Cancer Epidemiol. 2020. PMID: 31918180
-
No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Asian J Androl. 2017 Jul-Aug;19(4):414-417. doi: 10.4103/1008-682X.179528. Asian J Androl. 2017. PMID: 27232853 Free PMC article.
-
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20. Osteoporos Int. 2015. PMID: 25990353
-
Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.BMC Cancer. 2016 Mar 3;16:180. doi: 10.1186/s12885-016-2221-5. BMC Cancer. 2016. PMID: 26940836 Free PMC article. Review.
-
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18. Eur Urol Focus. 2020. PMID: 32690473 Review.
Cited by
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2024 Jan 2. doi: 10.1038/s41391-023-00785-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38167924
-
A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors.Cancers (Basel). 2023 Feb 14;15(4):1215. doi: 10.3390/cancers15041215. Cancers (Basel). 2023. PMID: 36831557 Free PMC article. Review.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.Prostate. 2022 Oct;82(14):1389-1399. doi: 10.1002/pros.24411. Epub 2022 Jul 12. Prostate. 2022. PMID: 35821621 Free PMC article.
-
Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies.JACC CardioOncol. 2022 Jun 21;4(2):223-234. doi: 10.1016/j.jaccao.2022.05.002. eCollection 2022 Jun. JACC CardioOncol. 2022. PMID: 35818552 Free PMC article.